| Ytd | -95.58% | |
| 1y | -90.75% |
| Open | 29.18 | Prev Close | 29.48 | Low | 29.10 | High | 30.21 | Mkt Cap | 30.12M |
| Vol | 4.09K | Avg Vol | 30.60K | EPS | -210.84 | P/E | N/A | Forward P/E | -5.68 |
| Beta | 1.31 | Short Ratio | 2.27 | Inst. Own | 25.53% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 27.16 | 200-d Avg | 153.32 | 1yr Est | 9.00 |
QNCX News
SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: Q
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: Q
Cantor Fitzgerald analyst Olivia Brayer Saunders reiterates Quince Therapeutics (NASDAQ:QNCX) wit
Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(12.31) per share which beat the ana
Completed acquisition of Orphai Therapeutics, adding LAM-001, an inhaled formulation of rapamycin fo
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Quince Therapeutics (NASDAQ:QNCX) wi
SOUTH SAN FRANCISCO, Calif. , June 30, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: Q
Leerink Partners analyst Joseph Schwartz initiates coverage on Quince Therapeutics (NASDAQ:QNCX)
Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Quince Therapeutics (NASDA
Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript
Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNC
The acquisition is structured as a stock-for-stock merger, pursuant to which all outstanding equity
Data from Phase 2a study of LAM-001 on top of standard of care in PH-ILD patients with refractory PH
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNC
SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- Quince Therapeutics, Inc. (Nasdaq: QNC
US stocks rose, Dow up 2.85%, Nasdaq up 3.33%, S&P 500 up 2.54%. Consumer discretionary shares u
Levi Strauss (LEVI) reported strong Q1 2026 results, raising revenue & earnings guidance. Other
Quince Therapeutics, Inc. (Nasdaq: QNCX) today announced the successful settlement of the company
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)---- $QNCX #biotech--Quince Therapeutics, Inc. (Nasdaq:
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have earned a consensus recomme
Shares of Quince Therapeutics, Inc. (NASDAQ: QNCX - Get Free Report) have received an average rating
Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capit
Quince Therapeutics shares surged 53% after hours Thursday following the engagement of LifeSci Capit
Quince Therapeutics Inc (NASDAQ: QNCX) stock is trading sharply lower Thursday after the biotech com
Quince Therapeutics stock is trading sharply lower Thursday after the biotech company followed up We
